-
BREAKING NEWS: Congress Passed the National Plan to End Parkinson's Act
On May 23, 2024, The U.S. Senate today unanimously passed the National Plan to End Parkinson’s Act, the first-ever federal legislation dedicated to ending Parkinson’s disease, sending the bill to President Biden’s desk to be signed into law. The bill passed with overwhelming bipartisan support in the U.S. House of Representatives last December.
-
NEW Parkinson's Disease Biomarker Found (aSyn-SAA)
Emerging evidence shows that alpha synuclein seed amplification assays (SAAs) have the potential to differentiate people with Parkinson's disease from healthy controls
-
JOIN US: 2024 Parkinson's Disease Therapeutics Conference
The Parkinson's Disease Therapeutics Conference (PDTC) is an annual fixture of MJFF that brings together 300 research and business development professionals from both academia and industry to showcase the most exciting and innovative research from MJFF’s research portfolio.
This year's PDTC will take place on Thursday, October 17th in New York City.
-
Landscape Intelligence Reports
MJFF provides Parkinson’s disease landscape reports to the researcher community including a target report, biomarker report, and clinical pipeline report - highlighting the latest advancements in therapeutic development.
-
Parkinson's Priority Therapeutic Clinical Pipeline Report
This report tracks therapies currently in clinical development for Parkinson’s disease as of late March 2024. It includes brief rationale and progress in key pipelines of therapeutic interest along with detailed listings of specific therapies, current development status and information about MJFF support (funding and/or non-funding connections).
-
Parkinson's Disease Biomarker Report
This report provides an overview of the Parkinson’s disease biomarkers landscape, with a focus on biochemical and molecular based assays that MJFF staff are currently monitoring. It is intended to reflect biomarkers at various stages of development and validation for the indicated intended uses (e.g., diagnosis, monitoring, etc.)
-
Parkinson's Disease Target Report
This report includes profiles of emerging and advanced targets along with a summary of the current status of the target as it relates to therapeutic devlopment, its connection to Parkinson's disease, MJFF’s investments to date and companies working on the respective target.
-
-
Parkinson's Disease is Moving Towards a Biologic Staging System
Recent biomarker advancements enable accurate detection of pathological α-synuclein in cerebral spinal fluid (CSF), suggesting redefining Parkinson's disease and dementia with Lewy Bodies as "neuronal α-synuclein disease" (NSD) based on in vivo detection, regardless of specific clinical symptoms. This proposal introduces a staging system, NSD-ISS, categorizing individuals by α-synuclein presence and functional impairment degree, aiming to facilitate early intervention trials and research.
-
Parkinson's Disease Research Exchange
The Parkinson’s Disease Research Exchange (PDRx) is a global network of scientists from academic labs, pharma/biotech companies, CROs and investors focused on assessing the current state of Parkinson's disease research, identifying key challenges, and translating findings into improved therapies.
Meetings are held virtually every Wednesday at 11:00 AM Eastern Standard Time (US).
-
Resources for Researchers
MJFF is committed to advancing research by providing in-kind resources for researchers including access to biospecimens, preclinical tools, open data, and can assist with study recruitment.
Questions?
Get in touch: Julianna Sullivan | jsullivan@michaeljfox.org